These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 39196505)

  • 1. Clinical features and mortality outcomes of patients with MASLD only compared to those with MAFLD and MASLD.
    Jiang M; Pan Z; George J; Eslam M
    Hepatol Int; 2024 Aug; ():. PubMed ID: 39196505
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characteristics and long-term mortality of individuals with MASLD, MetALD, and ALD, and the utility of SAFE score.
    Sripongpun P; Kaewdech A; Udompap P; Kim WR
    JHEP Rep; 2024 Oct; 6(10):101127. PubMed ID: 39290401
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differences in the prevalence of NAFLD, MAFLD, and MASLD according to changes in the nomenclature in a health check-up using MRI-derived proton density fat fraction.
    Park HJ; Lee S; Lee JS
    Abdom Radiol (NY); 2024 Sep; 49(9):3036-3044. PubMed ID: 38587630
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Steatotic liver disease-associated all-cause/cause-specific mortality in the United States.
    Kim D; Wijarnpreecha K; Cholankeril G; Ahmed A
    Aliment Pharmacol Ther; 2024 Jul; 60(1):33-42. PubMed ID: 38649335
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of nomenclature as metabolic associated steatotic liver disease on steatotic liver disease prevalence and screening: a prospective population survey in Asians.
    Wu T; Ye J; Mo S; Ye M; Li X; Li Q; Wang W; Zheng Q; Luo K; Zhang Y; Tu S; Che D; Gong R; Chen X; Miu R; Shao C; Sun Y; Zhong B
    J Gastroenterol Hepatol; 2024 Aug; 39(8):1636-1647. PubMed ID: 38695344
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exploring the landscape of steatotic liver disease in the general US population.
    Ciardullo S; Carbone M; Invernizzi P; Perseghin G
    Liver Int; 2023 Nov; 43(11):2425-2433. PubMed ID: 37592856
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Liver and atherosclerotic risks of patients with cryptogenic steatotic liver disease.
    Wang SW; Hsieh TH; Cheng YM; Wang CC; Kao JH
    Hepatol Int; 2024 Jun; 18(3):943-951. PubMed ID: 38227142
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MAFLD identifies patients with significant hepatic fibrosis better than MASLD.
    Pan Z; Al-Busafi SA; Abdulla M; Fouad Y; Sebastiani G; Eslam M
    Hepatol Int; 2024 Jun; 18(3):964-972. PubMed ID: 38717690
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of NAFLD, MAFLD and MASLD characteristics and mortality outcomes in United States adults.
    Song R; Li Z; Zhang Y; Tan J; Chen Z
    Liver Int; 2024 Apr; 44(4):1051-1060. PubMed ID: 38293788
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparing similarities and differences between NAFLD, MAFLD, and MASLD in the general U.S. population.
    Zou H; Ma X; Pan W; Xie Y
    Front Nutr; 2024; 11():1411802. PubMed ID: 39040926
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical profiles and mortality rates are similar for metabolic dysfunction-associated steatotic liver disease and non-alcoholic fatty liver disease.
    Younossi ZM; Paik JM; Stepanova M; Ong J; Alqahtani S; Henry L
    J Hepatol; 2024 May; 80(5):694-701. PubMed ID: 38286339
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Severity and Remission of Metabolic Dysfunction-Associated Fatty/Steatotic Liver Disease With Chronic Kidney Disease Occurrence.
    Gao J; Li Y; Zhang Y; Zhan X; Tian X; Li J; Wang R; He Y; Wang A; Wu S
    J Am Heart Assoc; 2024 Mar; 13(5):e032604. PubMed ID: 38390843
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MAFLD predicts cardiovascular disease risk better than MASLD.
    Pan Z; Shiha G; Esmat G; Méndez-Sánchez N; Eslam M
    Liver Int; 2024 Jul; 44(7):1567-1574. PubMed ID: 38641962
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Deciphering metabolic dysfunction-associated steatotic liver disease: insights from predictive modeling and clustering analysis.
    Mori K; Akiyama Y; Tanaka M; Sato T; Endo K; Hosaka I; Hanawa N; Sakamoto N; Furuhashi M
    J Gastroenterol Hepatol; 2024 Jul; 39(7):1382-1393. PubMed ID: 38629681
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MAFLD criteria are better than MASLD criteria at predicting the risk of chronic kidney disease.
    Pan Z; Derbala M; AlNaamani K; Ghazinian H; Fan JG; Eslam M
    Ann Hepatol; 2024; 29(5):101512. PubMed ID: 38710473
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of physical activity with MAFLD/MASLD and LF among adults in NHANES, 2017-2020.
    Li M
    Wien Klin Wochenschr; 2024 May; 136(9-10):258-266. PubMed ID: 38170220
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Breaking new ground: MASLD vs. MAFLD-which holds the key for risk stratification?
    Ramírez-Mejía MM; Jiménez-Gutiérrez C; Eslam M; George J; Méndez-Sánchez N
    Hepatol Int; 2024 Feb; 18(1):168-178. PubMed ID: 38127259
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of MAFLD and MASLD with all-cause and cause-specific dementia: a prospective cohort study.
    Bao X; Kang L; Yin S; Engström G; Wang L; Xu W; Xu B; Zhang X; Zhang X
    Alzheimers Res Ther; 2024 Jun; 16(1):136. PubMed ID: 38926784
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative associations of MASLD and MAFLD with the presence and severity of coronary artery calcification.
    Kang MK; Song J; Loomba R; Park S; Tak W; Kweon Y; Lee Y; Park JG
    Res Sq; 2024 Mar; ():. PubMed ID: 38496485
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fibrosis and steatotic liver disease in US adolescents according to the new nomenclature.
    Ma N; Bansal M; Chu J; Branch AD
    J Pediatr Gastroenterol Nutr; 2024 Aug; 79(2):229-237. PubMed ID: 38693784
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.